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17-β estradiol increases parvalbumin levels
in Pvalb heterozygous mice and attenuates
behavioral phenotypes with relevance to
autism core symptoms
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Abstract
Background: Autism spectrum disorder (ASD) is a group of neurodevelopmental disorders characterized by two
core symptoms: impaired social interaction and communication, and restricted, repetitive behaviors and interests.
The pathophysiology of ASD is not yet fully understood, due to a plethora of genetic and environmental risk factors
that might be associated with or causal for ASD. Recent findings suggest that one putative convergent pathway for
some forms of ASD might be the downregulation of the calcium-binding protein parvalbumin (PV). PV-deficient
mice (PV−/−, PV+/−), as well as Shank1−/−, Shank3−/−, and VPA mice, which show behavioral deficits relevant to
all human ASD core symptoms, are all characterized by lower PV expression levels.
Methods: Based on the hypothesis that PV expression might be increased by 17-β estradiol (E2), PV+/− mice were
treated with E2 from postnatal days 5–15 and ASD-related behavior was tested between postnatal days 25 and 31.
Results: PV expression levels were significantly increased after E2 treatment and, concomitantly, sociability deficits
in PV+/− mice in the direct reciprocal social interaction and the 3-chamber social approach assay, as well as
repetitive behaviors, were attenuated. E2 treatment of PV+/+ mice did not increase PV levels and had detrimental
effects on sociability and repetitive behavior. In PV−/− mice, E2 obviously did not affect PV levels; tested behaviors
were not different from the ones in vehicle-treated PV−/− mice.
Conclusion: Our results suggest that the E2-linked amelioration of ASD-like behaviors is specifically occurring in
PV+/− mice, indicating that PV upregulation is required for the E2-mediated rescue of ASD-relevant behavioral
impairments.
Keywords: ASD, Parvalbumin, 17-β estradiol, Estradiol treatment, Excitation/inhibition balance, Social behavior,
Ultrasonic vocalizations
Background
Autism spectrum disorder (ASD) core symptoms include
impaired sociability, communication problems, and re-
stricted or repetitive behaviors. The etiology of ASD re-
mains still unclear, but recent advances in genetics and
genomics have provided powerful tools to unraveling
how mutations in certain genes might result in ASD [1].
Although a plethora of genetic and environmental risk fac-
tors are associated with ASD [2], therapeutic approaches of
treating ASD subjects are rather limited and moreover,
most often do not target all core symptoms [3, 4].
Recent studies suggest that the calcium-binding pro-
tein parvalbumin (PV) is downregulated in some forms
of ASD. Most notably, Shank1−/− and Shank3−/− mice
and offspring from mice exposed to valproic acid in
utero (VPA mice), all validated mouse models for ASD,
are characterized by a prominent PV reduction in ASD-
associated brain regions [5, 6]. Genetically modified mice
deficient for PV (PV+/− and PV−/−) display behavioral
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deficits relevant to all human ASD core symptoms [7].
Moreover, the number of PV-immunoreactive (PV+)
GABAergic interneurons (hereafter termed Pvalb neu-
rons) was reported to be decreased in several cortical
areas in postmortem brains of ASD subjects [8]. However,
since no other marker than PV had been used to identify
the Pvalb neurons in that study, the decreased number of
PV+ neurons might equally well be the result of a de-
creased number of Pvalb neurons or of a decrease in PV
expression levels, as also acknowledged by the authors.
Preliminary results on two ASD brains also did not allow
to unequivocally ascribing the observed decrease of PV+
neurons to either mechanism [9]. Recently, RNA-seq and
qRT-PCR analyses of postmortem samples of frontal and
temporal cortex and cerebellum from 48 ASD individuals
and 49 controls revealed that the PVALB and SYT2
(synaptotagmin 2) genes were among the most strongly
downregulated ones in the ASD group [10]. In the absence
of clear evidence of Pvalb neuron loss in human ASD, but
of confirmed decreased PVALB mRNA levels in human
ASD individuals and additionally of PV protein levels in
mouse ASD models with construct and face validity, we
hypothesize that a decrease in PV levels might represent a
converging pathway of ASD pathophysiology, at least in a
subgroup of ASD cases.
Estrogen receptors β (ERβ) are strongly co-localized
with cortical Pvalb neurons [11], and several lines of indir-
ect evidence (reported as an increase in the number of PV
+ neurons) indicate that PV expression might be positively
modulated by 17-β estradiol (E2) [11–13]. Moreover, in
the rat pituitary cell line GH3 shown to be E2 responsive,
Pvalb was found to be one of the most E2-responsive
genes [14]. E2 administration was also found to signifi-
cantly increase Pvalb mRNA expression resulting in an
augmentation in the number of PV+ neurons in the CA1
pyramidal cell layer of rat hippocampus [15].
In this study, we aimed to increase PV expression in
PV+/− mice to possibly re-establish the state prevailing
in PV+/+ mice, both with respect to PV protein levels
and also behavior, for the latter applying assays with rele-
vance to all human ASD core symptoms [16, 17]. Our
approach consisted in supplementing PV+/+, PV+/−, and
PV−/− pups with E2 during the early postnatal period
from postnatal day (PND) 5 to 15. This time period was
chosen in order to cover the critical period of sexual
differentiation of neuronal circuits in rodents [18] and the
previously reported developmental onset of PV expres-
sion in the rodent brain [19, 20]. Moreover, Pvalb neu-
rons are implicated in the maturation of the cortical
GABA inhibitory circuitry, including the modulation
(initiation, termination) of critical developmental pe-
riods. A maturation index of Pvalb neurons proposed
by Gandal et al. [21] shows a highly significant correl-
ation between Pvalb neuron maturation status and PV
expression levels. Whether this is only correlative in na-
ture or possibly causal, i.e., PV “driving” Pvalb neuron
maturation to some extent, is currently unknown. It has
been shown before that E2 induces a “significant increase
of parvalbumin immunoreactive neurons” in both the
deep and superficial cortical layers in rat organotypic slice
cultures in vitro [12]. Moreover, in vivo, estrogens have
been shown to have a potential compensatory effect at
behavioral levels in animal models carrying mutations in
genes associated with ASD, such as the reeler heterozy-
gous mice (rl+/−) or the CNTNAP2−/− zebrafish ASD
model [22, 23]. However, none of these studies directly
proved whether E2 treatment leads to an upregulation of
PV at the transcript and/or protein levels.
In the present study, we found that E2 treatment of
PV+/− mouse pups increased PV protein levels and con-
sequently ameliorated ASD-associated social behavioral
deficits and decreased repetitive behavior in later life.
Thus, we provide a rationale for the positive effects of
E2 on ASD-linked behavior and propose that E2 treat-
ment should be given further attention as a potential
therapeutic strategy in ASD.
Methods
Mouse colonies and genotyping
Mice were group-housed and maintained as described be-
fore [7]. PV-deficient mice (PV−/−; B6.Pvalbtm1Swal) [24]
congenic with C57Bl/6J [25] were mated with C57Bl/6J
wild-type mice. Heterozygous breedings were set up in
order to be able to compare littermates. Day of birth was
defined as PND0; genotyping and paw marking was
carried out at PND2-3. Only male animals were used in
this study. All experiments were performed with permis-
sion of the local animal care committee (Canton of
Fribourg, Switzerland) and according to the present Swiss
law and the European Communities Council Directive of
24 November 1986 (86/609/EEC).
Estradiol treatment and determination of PV protein and
Pvalb mRNA levels
Litters, including all genotypes, were randomly assigned
to one of two experimental groups. In the first group,
pups were administered with vehicle (sesame oil; 10 μl/
day/pup), while the second group received 17-β estradiol
(E2; Sigma-Aldrich, Buchs, Switzerland) at a dose of
either 10 μg E2/day/pup (modified from [26]) or 50 μg
E2/day/pup (modified from [27]) in 10 μl vehicle be-
tween PND5-15. Thus, mice of all genotypes from the
same litter either received E2 or vehicle. Additional
details on mouse husbandry, mouse handling, and E2
administration are reported in Additional file 1. Pups
were weaned at PND22 and tested at (I) PND25 ± 1 for
reciprocal social interaction and communication, (II)
PND26 ± 1 for social approach in the three-chamber
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assay, and (III) PND31 ± 1 for repetitive, ritualistic be-
havior in the marble-burying test, following our previ-
ously established protocols [7, 28]. In all behavioral
assays, littermate controls were included and for all ex-
periments and analyses, experimenters were blinded
with respect to genotype and treatment. For the deter-
mination of PV protein and Pvalb mRNA levels, PND25
was chosen, the identical time point as for the start of
behavioral experiments; mice were sacrificed by cervical
dislocation; and brains were collected for Western blot
analyses and qRT-PCR analyses as described before [5].
Direct reciprocal social interaction and ultrasonic
vocalizations
Prior to testing, mice were socially isolated for 24 h in
order to enhance the level of social motivation. To
measure reciprocal social interaction behavior, pairs of
juvenile mice were allowed to socially interact at PND25
± 1 for 5 min after one mouse of the pair was habituated
to the test environment for 1 min. Same-treatment/
same-genotype pairs consisting of non-littermates were
used. Experimental details, including measurement of
ultrasonic vocalizations and behavioral analysis, have
been reported before [7]. Specifically, reciprocal social
interactions were recorded using a video camera. Direct
reciprocal social interactions were scored and analyzed
offline by an experienced observer with high reliability
(inter-rater correlation coefficient: r = 0.902; p < 0.001;
Pearson) using the Noldus The Observer XT 10.0 soft-
ware (Noldus Information Technology, Wageningen,
The Netherlands). Parameters of social behaviors in-
cluded facial sniffing (sniffing the nose and snout region
of the partner), anogenital sniffing (sniffing the anogeni-
tal region of the partner), following (walking straight
behind the partner, keeping pace with the one ahead),
push past (squeezing between the wall and the partner),
crawling under/over (pushing the head underneath the
partner’s body or crawling over or under the partner’s
body), social grooming (grooming the partner), and be-
ing socially inactive while having social contact (lying flat
or standing motionless, while maintaining close physical
contact with the partner). In addition to social behaviors,
non-social behaviors were measured and included rear-
ing (number of times an animal reared on its hind legs),
grooming (number of bouts of face, body, and genital
grooming movements) and digging (number of bouts of
digging in the bedding, pushing, and kicking it around).
Parameters of social behaviors, such as anogenital sniff-
ing, nose-to-nose sniffing, or following, were grouped
together, and a mouse was scored as “engaging in a so-
cial interaction” any time those behaviors were observed.
Results from reciprocal social interaction and ultrasonic
vocalization assays reflect the cumulative performance
of the two animals in the assay.
Social approach behavior in the three-chamber assay
Sociability in PV+/+, PV+/−, and PV−/− mice treated or
not with E2 was determined by the well-described three-
chamber social approach task for each individual mouse
[29]. The apparatus consisted of an open rectangular
box (60 × 40 × 40 cm) divided into three chambers by re-
tractable doors. Stranger stimulus mice were C57Bl/6J
mice of the same sex and age as the test subjects. The
test session began with a 10-min habituation period,
with the subject mouse free to move in all the empty
compartments of the chamber; in the meanwhile, a new
unfamiliar stranger mouse was habituated (10 min) to a
wire cup; an identical empty wire cup was used as novel
object. After the 10-min habituation period, the test subject
was briefly confined to the center chamber and the novel
object was placed in one of the side chambers, while the
novel mouse was placed on the other side. The location of
the novel object and the novel mouse were alternated be-
tween the left and right chambers across test subjects to
avoid a side preference bias. After both stimuli were posi-
tioned, the two side doors were simultaneously lifted and
the subject mouse had access to all three compartments for
10 min. The time spent in each compartment and entries
into each one and the time spent exploring the novel
mouse or the empty cup were manually scored by an obser-
ver blinded to the mouse genotype/treatment using two
stopwatches. Exploration of an enclosed mouse or of the
empty wire cup was scored positive, when the test mouse
was oriented with the head towards the cup within a 2-cm
distance between the head of the mouse and the cup, or
when climbing on the cup. Between tests, the apparatus
was cleaned with 0.1% acetic acid and water.
Marble-burying test
The marble-burying test consisted of introducing items
that a mouse can bury during a set period of time; mice
with an ASD-associated behavior often tend to engage in
a higher degree of digging (burying) than what is observed
in controls [28]. Mice were individually placed in Plexiglas
type III cages containing 5-cm deep clean bedding with 20
ceramic marbles (14 mm diameter) arranged in 5 × 4
evenly spaced rows as described before [30]. Test duration
was 30 min. Marbles were considered buried, if more than
half of a marble was covered with bedding. A greater
number of buried marbles was considered as an indication
for increased repetitive behavior.
Statistical analysis
For analysis of direct reciprocal social interaction and
ultrasonic vocalizations in juvenile mice, two-way ANO-
VAs with the between-subject factors genotypes (PV+/+,
PV+/−, PV−/−) and treatment (vehicle vs. E2) plus the
covariate age of subject mice (PND) were calculated. In
order to test whether differences in direct reciprocal
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social interaction behavior and the emission of ultra-
sonic vocalizations emerged over time during testing,
ANOVAs for repeated measurements with the same
between-subject factors plus the covariate age of subject
mice and the within-subject factor test duration were
performed. Paired t tests were used to compare the like-
lihood of the occurrence of a social behavior in response
to a social behavior, and one-sample t tests for compari-
sons with chance levels. Three-way ANOVAs for re-
peated measurements with the within-subject factor
preference (mouse vs. object) and the between-subject
factors genotype and treatment (vehicle vs. E2) were
used to analyze social approach behavior in the three-
chamber assay. Marble-burying behavior was analyzed
using a two-way ANOVA with the between-subject fac-
tors genotype and treatment (vehicle vs. E2). ANOVAs
were followed by LSD post hoc analysis or paired/un-
paired Student’s t tests when appropriate. Western blot
analysis was performed, and protein levels were com-
pared between genotypes and treatments using planned
Student’s t tests. For all the experiments, a p value < 0.05
was considered statistically significant. Data were ana-
lyzed using IBM SPSS Statistics 22 (Armonk, USA) and
GraphPad Prism software (San Diego, USA).
Results
Here, we demonstrate that E2 upregulates PV expression
in PV+/− mice leading to an amelioration of the ASD-
related phenotypes previously described for PV-deficient
(PV+/−, PV−/−) mice [7]. Conversely, in most assays, E2
treatment of PV+/+ mice unexpectedly provoked ASD-
like behaviors, whereas in PV−/− mice, E2 had no sig-
nificant effect in all behavioral tests carried out.
PV upregulation via 17-β estradiol administration
Based on direct and indirect evidence linking PV expres-
sion levels with estradiol [12, 22], we investigated whether
E2 upregulates PV expression in PV+/− mice. PV levels in
PV+/− forebrain samples were significantly lower, i.e., in
the order of 50% compared to PV+/+ samples (p = 0.003;
Fig. 1), in line with previous findings [5, 31, 32] and PV
was completely absent in PV−/− mouse extracts (not
shown). Both E2 treatments (10 or 50 μg/day) did not
significantly affect PV expression levels in PV+/+ animals
at PND25. Importantly, E2 treatment of PV+/− mice in
the period from PND5 to PND15 resulted in a persistent
increase in PV determined at PND25 (10 μg E2: p = 0.011;
50 μg E2: p = 0.041; Fig. 1). Since no significant differences
in the degree of recovery of PV expression were observed
Fig. 1 Western blot analysis and RT-qPCR of forebrain samples from PV+/+ and PV+/− mice either vehicle-treated (−) or E2-treated (+) from
PND5-15. a Left: representative Western blots of PV (Mr: 12 kDa) and GAPDH (Mr: 35 kDa; normalization signal) are shown. Middle: quantitative
analysis of PV signals in mice treated with 10 μg E2/day/pup. Data are obtained from three independent experiments and are shown as mean ±
SEM. Results are expressed as a percentage of normalized PV levels as measured in vehicle-treated PV+/+ samples (set as 100%). GAPDH was used
for the normalization of the PV signals. Right: RT-qPCR analysis of forebrain samples of PV+/+ and PV+/− mice. Pvalb mRNA levels were normal-
ized to 18S mRNA levels and expressed as fold change. Data from three independent experiments were pooled and are shown as mean ± SEM. b
Representative Western blots (left) and quantitative analysis of PV signals from samples derived from mice treated with 50 μg E2/day/pup (right).
PV signal quantification was done as in a. Asterisks represent *p < 0.05, **p < 0.01, respectively
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in PV+/− animals treated with 10 or 50 μg E2, the lower
dose was chosen for all behavioral experiments.
To evaluate how well Pvalb mRNA and protein expres-
sion levels correlate after E2 administration, we performed
RT-qPCR analysis. Pvalb mRNA levels of E2-treated
(10 μg) PV+/− mice were significantly increased, to a simi-
lar extent as PV protein levels (Fig. 1a), in comparison
with PV+/− vehicle-treated mice (p = 0.041). This is sug-
gestive of a modulation of PV via E2 at the transcriptional
level, in line with previous studies [14]. No changes were
seen in PV+/+ animals after E2 administration (Fig. 1a).
Direct reciprocal social interaction and ultrasonic
vocalizations
Direct reciprocal social interaction was tested in PND25
± 1 juvenile mice. The time spent in reciprocal social
interactions was visibly affected by E2 treatment in a
genotype-dependent manner (genotype: p = 0.805; treat-
ment: p = 0.848; genotype x treatment: p = 0.044; Fig. 2a).
In vehicle-treated PV−/− mice, we observed a tendency
to engage less in reciprocal social interactions (− 28%
interaction time) compared to PV+/+ littermate controls
(p = 0.077), while the decrease was found insignificant in
PV+/− mice (p = 0.269). In a previous study, a similar
decrease in social interaction time had been observed;
however, the overall effect was slightly larger (− 36%)
and also significant in the PV+/− mouse group [7].
While in the group of E2-treated PV+/+ mice, the time
spent in reciprocal social interactions was significantly
decreased compared to the vehicle-treated PV+/+ mice
(p = 0.037); no differences in interactions were observed
in E2-treated PV+/− and PV−/− mice in comparison to
corresponding vehicle-treated mice (p = 0.475 and p =
0.147, respectively). However, there was a notable tendency
of increase in comparison to the E2-treated PV+/+ litter-
mate controls (p = 0.056 and p = 0.073, respectively), an
effect that was mostly attributable to a “worsening” of the
E2-treated PV+/+ mice. Along the 5-min examination
period, the time spent in social interactions was rather con-
stant in all groups, with a trend for a decrease towards the
end (Fig. 2b). When analyzing the social behavior reper-
toire in detail, its richness and reciprocal character were
found to be strongly dependent on genotype (Fig. 2c).
While vehicle-treated PV+/+ mice displayed a signifi-
cant preference for engaging in another social behavior
following a previous one in ~ 65% of the cases (~ 35%
for non-social behavior; p = 0.011 vs. chance level), no
such preference was seen in vehicle-treated PV+/− and
PV−/− mice, with social behaviors following in ~ 57
and ~ 53% of cases, respectively (p = 0.165 and p =
0.665 vs. chance level, respectively). The genotype-
dependent effect size was approximately of the same
magnitude as observed in our previous study (com-
pared to Fig. 1d in [7]). In E2-treated mice, however, a
different pattern emerged (Fig. 2c’). Most remarkably,
in E2-treated PV+/− mice, a social behavior was followed
by another one in ~ 62% of cases (p = 0.024 vs. chance
level), almost reaching the situation prevailing in “normal,”
i.e., vehicle-treated PV+/+ mice. While E2 treatment had
no prominent effect in PV−/− mice, with social behaviors
following in ~ 57% of cases (p = 0.359 vs. chance level), E2
treatment had detrimental effects in PV+/+ mice, with so-
cial behaviors following in only ~ 55% of cases (p = 0.614
vs. chance level). Representative ethograms of mouse pairs
are depicted in Fig. 2d, d’. There was no evidence for geno-
type × treatment interaction effects on non-social behav-
iors, including rearing, grooming, and digging behavior
(Fig. 2d, d’, all p values > 0.100). The different social behav-
ior components (e.g., facial sniffing, following, etc.) as
shown in the ethograms (Fig. 2d, d’) were statistically
analyzed in more detail, i.e., for each behavior component
independently and results are presented in Additional file 1.
Only in one of the social behaviors (social grooming), we
observed a weak genotype × treatment interaction (p =
0.03) indicating that behaviors grouped as “social behavior”
represent general effects that cannot be fragmented into
meaningful individual social behavior components.
Ultrasonic vocalization emission rates during recipro-
cal social interactions tended to be weakly affected by
E2 treatment in a genotype-dependent manner (geno-
type: p = 0.355; treatment: p = 0.298; genotype × treat-
ment: p = 0.090; Fig. 3a). Numbers of vocalizations were
significantly decreased in vehicle-treated PV−/− mice
compared to the corresponding PV+/+ group (p = 0.047;
Fig. 3a). An intermediate phenotype was observed in
vehicle-treated PV+/− mice, although the decrease in
vocalization numbers compared to PV+/+ was not signifi-
cant (p = 0.303), likely due to the large variations between
individual mice of all genotype and treatment groups
(Fig. 3a). Of note, genotype differences in vehicle-treated
mice were less prominent than observed previously [7],
possibly as the result of extensive/prolonged mouse hand-
ling during daily E2 or vehicle treatments (see discussion).
Call numbers were significantly decreased in E2-
treated PV+/+ compared to vehicle-treated PV+/+
mice (p = 0.025), but call numbers were essentially
unchanged in E2- or vehicle-treated PV+/− and also
PV−/− groups (p = 0.723 and p = 0.582, respectively)
(Fig. 3a). The time course of vocalizations, i.e., the
highest numbers of calls occurring within the first 2 min
after the addition of the second mouse, followed by a grad-
ual decline (Fig. 3b) was similar as reported before [7].
There was no evidence for genotype × treatment inter-
action effects on acoustic call features, including call
duration (Fig. 3c), peak frequency (Fig. 3d; all p values >
0.100) and frequency modulation (p = 0.083; Fig. 3e).
Irrespective of genotype and treatment, the emission of
ultrasonic vocalizations was highly positively correlated
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with the time spent in reciprocal social interaction
(r = 0.791, p < 0.001; Fig. 3f ). Representative spectro-
grams are depicted in Fig. 3g for a pair of vehicle-treated
or E2-treated PV+/− mice; the other four groups of mice
revealed very similar patterns of calls (not shown).
Social approach behavior in the three-chamber assay
In the often applied three-chamber test [29], sociability is
defined as preference for a novel mouse (subject; S) over a
novel object (empty wire cup; O). Preference is typically
assessed by means of time spent in chambers containing
Fig. 2 Reciprocal social interaction test. a The total social interaction time displayed by pairs of the same genotype during the 5-min social inter-
action period in the cohorts of PV+/+, PV+/−, and PV−/− mice, vehicle-treated or E2-treated. Asterisk represents *p < 0.05. b Time course of time
spent in social interaction per 1-min bin (dashed line indicates introduction of partner mouse). Data are presented as mean ± SEM. c Percentage
of non-social vs. social behavior following social behavior in PV+/+ wild-type littermate control mice, PV+/− heterozygous mice, and PV−/− mice
treated with vehicle (c) or E2 (c’). The dashed line indicates 50% chance level. Black bar: social; striped bar: non-social. Asterisk represents
p < 0.05 vs. non-social. Hashtag represents p < 0.05 vs. 50% chance level. d Representative ethograms of social and non-social behavior displayed
during juvenile reciprocal social interactions by a PV+/+ wild-type littermate control mouse, a PV+/− heterozygous mouse, and a PV−/− null mu-
tant mouse treated with vehicle (d; left) or E2 (d’; right)
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Fig. 3 Analysis of ultrasonic vocalizations between PV+/+, PV+/−, and PV−/− mouse pairs. Irrespective of treatment, all genotypes displayed
similar call emission patterns. a Total number of calls emitted during the 5-min social interaction period; asterisks represent *p < 0.05. b
Time course for the number of ultrasonic vocalizations emitted for each 1-min time bin across the 5-min social interaction period, plus 1 min
habitation (dashed line indicates introduction of partner mouse). Data are presented as mean ± SEM. c Average call duration, d peak frequency
and e frequency modulation of emitted calls during the 5-min social interaction period. f Correlation between ultrasonic vocalizations and time
spent in social interaction for each animal. g Representative spectrograms of ultrasonic vocalizations emitted during juvenile reciprocal social
interactions of a vehicle-treated (upper traces) and an E2-treated (lower traces) PV+/− mouse are shown
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the novel mouse versus the novel object. This preference
was clearly genotype-dependent (preference: p = 0.002;
preference × genotype: p = 0.014; Fig. 4a; data are addition-
ally presented as bar graphs in Additional file 1: Figure
S3A). Vehicle-treated PV+/+ mice showed a strong prefer-
ence for the chamber containing the novel mouse com-
pared to the one with the novel object (p = 0.001), while no
such preference was observed in vehicle-treated PV+/− and
PV−/− mice (all p values > 0.100). Mice from the latter two
groups (PV+/−, PV−/−) showed an almost equal interest in
the two chambers. E2 treatment slightly decreased the S/O
ratio in PV+/+ mice; however, mice still spent significantly
more time in the S chamber (p = 0.046). E2 treatment of
PV+/− and PV−/− mice did not affect the time spent in the
S and O compartments (preference × treatment: p = 0.165;
preference × genotype × treatment: p = 0.335).
Fig. 4 E2 administration differently affected sociability of PV+/+, PV+/−, and PV−/− mice tested in the three-chamber assay. a Paired graphs of
time spent in the chamber with the novel mouse (S) or the object (O) during the 10-min social interaction period plotted for each mouse; a
negative slope (S > O) is characteristic of a “social” mouse. b Sniffing/exploration time spent close to the subject mouse, i.e., within 2 cm from
the stranger/empty wired cup. c Percentage of “social” mice defined as animals with sniff duration time (S) > (O) during the 10-min test phase. d
Preference index (stranger vs. object sniffing time divided by the total exploration time in the compartments containing S and O) fold change.
Values close to “0” indicate no preference for the stranger mouse. Asterisks represent *p < 0.05; **p < 0.01; ***p < 0.001; n.s.: not significant. Hash-
tags represent significant preference for the stranger mouse over the object ##p < 0.01; ###p < 0.001
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More relevant than a mouse’s simple presence in the
S- and O-containing chamber of the cage and thus
representing a more sensitive measure of sociability is
the measurement of sniff duration, i.e., the time spent
within a 2-cm distance from the wire cup [16, 33]. With
this measurement, genotype differences were even more
prominent (preference: p < 0.001; preference × genotype:
p = 0.009; Fig. 4b; data presented as bar graphs in
Additional file 1: Figure S3B). In congruence with the re-
sults shown in Fig. 4a, vehicle-treated PV+/+ mice spent
significantly more time in sniffing the novel mouse than
the novel object (p < 0.001), while vehicle-treated PV+/−
mice showed a much weaker (if any; p = 0.057) and PV−/−
mice no such preference for the novel mouse (p = 0.126).
The more sensitive sociability-related measure “sniff dur-
ation” further revealed that the preference for the novel
mouse over the novel object was clearly modulated by E2
treatment in a genotype-dependent manner (preference ×
treatment: p = 0.265; preference × genotype × treatment:
p = 0.042; Fig. 4b and Additional file 1: Figure S3B). E2
treatment of PV+/− mice considerably increased the dur-
ation of sniffing the novel mouse, resulting in a substantial
preference towards it (p < 0.001), to levels observed in E2-
treated or vehicle-treated PV+/+ mice. In the E2-treated
PV+/− group, the percentage of mice with S > O sniff time
rose to 90%, similar to values in the vehicle- (14 out of 15;
93.3%) and E2-treated (12 out of 14; 85.7%) PV+/+ group
(Fig. 4c), indicative of an almost complete E2-mediated
rescue in otherwise less social PV+/− mice. Such a change
was not observed in E2-treated PV−/− mice (p = 0.342).
E2-treated PV+/+ mice still displayed a preference for the
novel mouse (S) over the novel object (O) (p = 0.008);
however, such a preference was notably decreased. Of
note, the results obtained in the three-chamber social ap-
proach assay were robust insofar, as the result pattern did
not change depending on whether climbing on the cup
was included in the sniffing analysis or not. In fact, the
time that mice spent on top of either the stimulus
(S) or object (O) cup closely resembled the picture
observed for sniff time, simply on a much smaller
time scale (compare Additional file 1: Figures S3B
and S4A).
In an additional exploratory approach, this genotype
effect was also evident when comparing the often used
preference index, defined as the numerical difference
between time spent exploring the targets (subject vs. ob-
ject, S-O) divided by the total time spent in the two
compartments containing either target, as described pre-
viously [34, 35]. A clear preference for the novel mouse
was observed in vehicle-treated PV+/+ mice (p < 0.001),
while such a preference was very weak for vehicle-
treated PV+/− mice (p = 0.070) and not observed in PV
−/− mice (p = 0.277), resulting in significant group differ-
ences (p = 0.005 and p = 0.002 vs. PV+/+, respectively;
Fig. 4d). E2 treatment significantly increased the prefer-
ence index in PV+/− mice (p < 0.001), while this was not
the case for E2-treated PV−/− mice (p = 0.356). There
was still a significant, however, smaller (compared to
vehicle-treated PV+/+) preference for the novel mouse
in E2-treated PV+/+ mice (p = 0.008). In line with the
results on reciprocal social interactions (Fig. 2a), soci-
ability tested in the social approach assay was again de-
creased in E2-treated PV+/+ mice compared to vehicle-
treated PV+/+ mice (Fig. 4d; p = 0.034), supporting the
adverse effect of E2 treatment in “healthy” PV+/+ mice.
To exclude the possibility that the observed differences in
preference might be the result of impaired or reduced
locomotor activity in the six groups, the number of entries
into the two chambers was determined and found to be un-
changed (preference: p = 0.843; preference × genotype: p =
0.201; preference × treatment p = 0.818; preference ×
genotype × treatment: p = 0.693). However, general loco-
motor activity was affected (genotype: p = 0.003; treatment:
p = 0.896; genotype × treatment: p = 0.009). In fact, under
vehicle conditions genotypes did not differ (p = 0.765), yet
under E2 treatment conditions, genotypes differed (p =
0.001) and PV+/− mice displayed more entries than PV+/+
and PV−/− mice (p = 0.001 and p = 0.006, respectively),
possibly reflecting their more vigorous attempts to es-
tablish social contact (Additional file 1: Figure S3C).
Marble-burying test
To test repetitive behavior, we performed the marble-
burying test [28]. Marble burying was visibly affected by
E2 treatment in a genotype-dependent manner (geno-
type: p = 0.471; treatment: p = 0.982; genotype x treatment:
p = 0.009; Fig. 5a). Vehicle-treated PV+/− and PV−/− mice
buried more marbles compared to the corresponding
PV+/+ mice (p = 0.046 and p = 0.053, respectively), in
support of increased repetitive behavior in mice with
reduced or absent PV levels [7]. While E2 treatment
of PV+/+ mice increased their marble burying behavior
(p = 0.051), E2-treated PV+/− mice buried less marbles
than their corresponding vehicle-treated PV+/− group
(p = 0.011). No E2 effects were observed in PV−/−
mice (p = 0.832). Also the marble-burying test hints
towards a common effect of E2 administration: an in-
crease (worsening) in ASD-associated behaviors in PV+/+
and an attenuation (improvement) of ASD-associated
behaviors in PV+/− mice (Fig. 5b), closely approaching
the behavior of vehicle-treated PV+/+ mice.
Discussion
PV-deficient mice (PV+/−, PV−/−) represent a new gen-
etic mouse model of ASD, displaying a behavioral pheno-
type characterized by impairments in social interaction,
communication, and perseveration [7]. In these mice, PV
expression levels are downregulated/absent, while the
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number of Pvalb neurons is unaltered compared to PV+/+
mice [5]. The same holds true for Shank1−/−, Shank3−/−,
and VPA mice [6, 36], three well-established mouse
models for ASD [28, 37–41]. Thus, we addressed the
question whether the direct upregulation of PV via neo-
natal administration of E2 might ameliorate or even
abrogate the ASD phenotype displayed by male juvenile
PV+/− mice. E2 administration in PV+/− mice increased
PV expression to levels closely approaching vehicle-
treated PV+/+ mice; at the behavioral level, this coincided
with an attenuation of the ASD-related phenotypes. Most
evidently, the richness and reciprocal character of E2-
treated PV+/− mice was substantially increased, as quanti-
fied by a preference for engaging in another social behavior
following a previous one. Such a preference was repeatedly
reported in mice displaying intact sociability, including, but
not limited to [42], i.e., control (PV+/+) mice [7].
Consistently, a preference for engaging in another social
behavior following a previous one was also seen in vehicle-
treated PV+/+ mice in the present study, but not in PV+/−
and PV−/− mice. Importantly, such a preference was also
evident in E2-treated PV+/−mice, almost reaching the situ-
ation of vehicle-treated PV+/+ mice, while E2 treatment
had no positive effect in PV−/− mice. This suggests that
our recently established approach to quantify the prefer-
ence for engaging in another social behavior following a
previous one offers a new and unique possibility to assess
treatment effects on the richness and the heterogeneity of
the direct reciprocal social behavior repertoire displayed by
juvenile mice. However, while this appears a promising
strategy, our approach to quantify the preference for en-
gaging in another social behavior is new and its validity
and potential in revealing treatment effects thus would
merit an independent dedicated validation study. There,
comparing several ASD mouse models with known social
deficits would reveal whether this parameter might be
helpful for the identification/validation of an ASD-like
phenotype in mice.
Supporting the results from the direct reciprocal social
interaction test, the “sniff duration” time, being the most
sensitive parameter in the three-chamber social approach
assay, revealed a pro-social effect of E2 treatment exclu-
sively in PV+/− mice. The lack of social preference seen in
vehicle-treated PV+/− and PV−/− mice is consistent with
their altered reciprocal social interaction behavior when
compared to PV+/+ mice. Only in PV+/− mice, E2 treat-
ment considerably increased the sniffing S/O ratio of indi-
vidual mice; 90% showed a preference for the novel mouse
vs. 61% in vehicle-treated animals, indicative of an E2-
mediated increase in sociability in otherwise “non-social”
PV+/− mice.
Communication deficits in PV+/− and PV−/− mice ob-
served before [7], were also seen in vehicle-treated PV+/−
and PV−/− mice, but were only significant in PV−/− mice.
E2 treatment had no effect in PV+/− and PV−/− mice but
caused a reduction of call number in PV+/+ mice. The ab-
sence of a treatment effect on ultrasonic vocalizations
might be attributable to the prolonged postnatal handling
during E2/vehicle administration. In agreement, the average
number of calls in vehicle-treated PV+/+ mice (556) was
much higher than in the previous study where mice were
subjected to substantially less handling (average 355 in PV
+/+ mice; [7]). It is known that neonatal handling increases
call emission in pups, which in turn, serves to increase ma-
ternal care [43, 44]. The stressful context associated with
extensive handling [45] is the most likely explanation for
Fig. 5 Performance of PV+/+, PV+/−, and PV−/− mice in the marble-burying test. a Total number of buried marbles in vehicle-treated and E2-
treated mice; asterisks represent *p < 0.05. b Numerical difference within the same genotype groups between E2-treated and vehicle-treated mice.
Negative values below “0” indicate attenuation of repetitive, ritualistic behavior; values above “0” indicate an E2-mediated increase of marble-
burying behavior, i.e., an increase in ASD-associated behavior
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the increased production of ultrasonic vocalizations in all
genotypes compared to our previous study [7], possibly
masking genotype-dependent effects of E2. As assessment
of repetitive behaviors, we performed the marble-burying
test; E2-treated PV+/− animals performed better (i.e., bur-
ied less marbles) than vehicle-treated PV+/− mice, consist-
ent with previous findings showing that female sex
hormone levels modulate marble-burying behavior [46, 47].
Moreover, the overall rather low numbers of marbles buried
is likely the result of the juvenile age (PND31), when mice
were tested; a significant age-dependent increase in marble-
burying behavior from PND24 (≈ 10%) to PND40 (≈ 30%
marbles buried) has been observed before [46].
Taken together, our results confirm that E2 can ameli-
orate the investigated ASD-like symptoms, in line with
previous findings supporting a role for E2 as a promising
candidate in amelioration of ASD-related phenotypes
[22, 23]. In particular, we observed a ≈ “rescue effect” in
sociability tests and amelioration of repetitive behaviors
selectively in E2-treated PV+/− mice, but not in the PV
+/+ and PV−/− groups. It is important to remark that
E2 had no significant effect on PV protein levels in ju-
venile PV+/+ and PV−/− mice; thus, any effect observed
in these mice after E2 treatment excludes PV being the
effector of the putative changes. Nevertheless, E2 might
have effects per se, previously evidenced by its role in
modulation of social behavior [48] and modulation of
neural circuits via direct or indirect activation of mul-
tiple downstream signaling pathways [49]. In contrast to
primates, where brain circuits are primarily masculinized
by the action of androgens, it is presumed that in the
brain of rodents, such masculinizing effects are mainly
mediated by estrogens [50]. Repetitive exposure to estro-
gens in neonatal PV+/+ males from PND5 to PND15
might thus induce an “extreme male brain,” according to
the theory proposed by Baron-Cohen [51]. This might ex-
plain the “anti-social” effect of E2 treatment in PV+/+ mice
(reduced ultrasonic vocalizations, decreased sociability) as
well as the increase of repetitive behaviors (higher number
of buried marbles compared to controls).
Our results indicate that E2 is sufficient to partially re-
verse ASD-relevant behaviors, if it is associated with a
reinstatement of PV levels similar to the ones seen in
PV+/+ mice. The E2-mediated re-establishment of PV
levels is assumed to also restore the electrophysiological
phenotypes associated with the absence of PV, i.e., stron-
ger short-term facilitation, increased excitability, in-
creased regularity of fast-spiking interneuron firing in
PV−/− mice [52]. The presumed functional restoration
of the Pvalb-neuron containing networks is then likely
to also restore the excitation/inhibition (E/I) ratio in E2-
treated PV+/− mice, the E/I balance assumed to be a
key factor in ASD [53, 54]. Our results in male PV+/+
mice, however, indicate that E2 treatment in a situation
defined by a balanced E/I ratio actually leads to a “wors-
ening” in communication and sociability tasks and an in-
crease in repetitive behaviors.
An optimal range of PV circuit function in the insular
cortex has been proposed before, where either an imbal-
ance towards more excitation or more inhibition was
shown to impair multisensory integration in several
ASD mouse models including Shank3 and Mecp2 knock-
out mice [55]. In the latter, the trajectory of functional
maturation of Pvalb neurons in the primary visual cortex
is accelerated upon vision onset (advanced onset and
closure of the critical period), based on higher expres-
sion levels of PV and GAD67, vGAT, perineuronal nets,
and enhanced GABA transmission among Pvalb neurons
at PND15 [56]. In the ASD knockout mouse model for
BMP/RA-inducible neural-specific protein 1 (Brinp1
−/−), the higher density of PV+ neurons in the somato-
sensory cortex and medial hippocampus in adult mice,
without indication of altered neuronal proliferation and
apoptosis during embryonic development, is indicative
of increased PV levels associated with the ASD pheno-
type [57]. Thus, putative E2-mediated alterations in the
trajectory of PV expression and/or associated Pvalb net-
work maturation in E2-exposed PV+/+ mice might be
responsible for the appearance of an ASD phenotype
possibly linked to accelerated maturation.
The identification of targets for the E2-mediated nega-
tive effects on the behavior of PV+/+ mice requires
further investigations. It remains to be investigated
whether E2-mediated increases in PV in other ASD
mouse models, including Shank1, Shank2, and Shank3
knockouts [58, 59] or VPA mice consequently amelio-
rates ASD-associated behaviors. If successful, E2 treat-
ment and/or other means of selective PV upregulation
might represent a new avenue towards improvement,
i.e., “normalization” of behavior in human ASD.
Conclusions
Our study confirms that PV-deficient mice (PV+/− and
PV−/−) show a discernable ASD-like phenotype. ASD-
associated behaviors (decreased social interaction, aug-
mented repetitive behaviors) displayed by PV+/− mice
are strongly ameliorated, if PV expression is restored
close to PV+/+ levels via early postnatal E2 administra-
tion. In PV−/− mice, where E2 treatment has obviously no
effect on PV levels, the ASD-like phenotype persists. Un-
expectedly, in E2-treated PV+/+ mice, ASD-associated
behaviors arise. Our results point towards a key role of PV
upregulation in PV+/− mice with regard to the amelior-
ation of ASD-like behaviors. An increase in PV expression
mediated by E2 in other ASD mouse models with reduced
PV levels might also improve ASD-like behavior and pos-
sibly represent a point of convergence facilitating the
search for new therapeutic approaches in ASD.
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Additional file 1: Supplemental information on experimental
details. Figure S1 A) Details on mouse husbandry and B) selection of
the tested mice. Figure S2 Methodological details on mouse handling,
E2 administration and mouse weights. Figure S3 Results from 3-chamber
social approach assay presented as bar graphs (A and B) and number of
entries in S and O chamber (C). Figure S4 Analysis of cup climbing time
during the 3-chamber social approach assay. Table S1 Component ana-
lysis of behaviors scored in social reciprocal interaction. (DOCX 3208 kb)
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